bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · IEX Real-Time Price · USD
+0.090 (8.57%)
Jul 22, 2024, 4:00 PM EDT - Market closed

bluebird bio Statistics

Total Valuation

bluebird bio has a market cap or net worth of $219.73 million. The enterprise value is $340.47 million.

Market Cap 219.73M
Enterprise Value 340.47M

Important Dates

The next estimated earnings date is Tuesday, August 6, 2024, before market open.

Earnings Date Aug 6, 2024
Ex-Dividend Date n/a

Share Statistics

bluebird bio has 192.74 million shares outstanding. The number of shares has increased by 33.79% in one year.

Shares Outstanding 192.74M
Shares Change (YoY) +33.79%
Shares Change (QoQ) +0.38%
Owned by Insiders (%) 0.36%
Owned by Institutions (%) 58.94%
Float 108.85M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 9.71
Forward PS 2.38
PB Ratio 0.95
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 15.67
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.36.

Current Ratio 1.55
Quick Ratio 1.24
Debt / Equity 1.36
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage 11.94

Financial Efficiency

Return on equity (ROE) is -34.30% and return on invested capital (ROIC) is -25.87%.

Return on Equity (ROE) -34.30%
Return on Assets (ROA) -14.40%
Return on Capital (ROIC) -25.87%
Revenue Per Employee $67,263
Profits Per Employee -$282,251
Employee Count 323
Asset Turnover 0.03
Inventory Turnover n/a


In the past 12 months, bluebird bio has paid $30,000 in taxes.

Income Tax 30,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -70.31% in the last 52 weeks. The beta is 0.85, so bluebird bio's price volatility has been lower than the market average.

Beta (5Y) 0.85
52-Week Price Change -70.31%
50-Day Moving Average 1.01
200-Day Moving Average 1.72
Relative Strength Index (RSI) 55.03
Average Volume (20 Days) 6,039,630

Short Selling Information

The latest short interest is 30.71 million, so 15.93% of the outstanding shares have been sold short.

Short Interest 30.71M
Short Previous Month 29.48M
Short % of Shares Out 15.93%
Short % of Float 28.22%
Short Ratio (days to cover) 4.72

Income Statement

In the last 12 months, bluebird bio had revenue of $21.73 million and -$91.17 million in losses. Loss per share was -$0.60.

Revenue 21.73M
Gross Profit -2.19M
Operating Income -136.15M
Pretax Income -91.14M
Net Income -91.17M
EBITDA -95.08M
EBIT -99.46M
Loss Per Share -$0.60
Full Income Statement

Balance Sheet

The company has $174.29 million in cash and $303.71 million in debt, giving a net cash position of -$129.41 million or -$0.67 per share.

Cash & Cash Equivalents 174.29M
Total Debt 303.71M
Net Cash -129.41M
Net Cash Per Share -$0.67
Equity (Book Value) 222.54M
Book Value Per Share 1.15
Working Capital 88.12M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$277.48 million and capital expenditures $191.85 million, giving a free cash flow of -$85.64 million.

Operating Cash Flow -277.48M
Capital Expenditures 191.85M
Free Cash Flow -85.64M
FCF Per Share -$0.79
Full Cash Flow Statement


Gross margin is -10.08%, with operating and profit margins of -626.69% and -419.62%.

Gross Margin -10.08%
Operating Margin -626.69%
Pretax Margin -419.48%
Profit Margin -419.62%
EBITDA Margin -437.65%
EBIT Margin -457.81%
FCF Margin -394.16%

Dividends & Yields

bluebird bio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -33.79%
Shareholder Yield -33.79%
Earnings Yield -43.20%
FCF Yield -40.58%

Analyst Forecast

The average price target for bluebird bio is $5.71, which is 400.88% higher than the current price. The consensus rating is "Hold".

Price Target $5.71
Price Target Difference 400.88%
Analyst Consensus Hold
Analyst Count 9
Revenue Growth Forecast (5Y) 126.30%
EPS Growth Forecast (5Y) -52.81%
Stock Forecasts

Stock Splits

The last stock split was on November 5, 2021. It was a forward split with a ratio of 1544:1000.

Last Split Date Nov 5, 2021
Split Type Forward
Split Ratio 1544:1000


bluebird bio has an Altman Z-Score of -9.38 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -9.38
Piotroski F-Score 4